Over the past few decades, the number of patients with diabetes mellitus, especially type 2 (T2DM), has risen to 350 million worldwide, with projections that by 2035, the number will have risen to 592 million (1 in 10 adults).

Pravastatin and fenofibrate therapy consistently produce complementary benefits on the overall atherogenic lipid profile in patients with mixed dyslipidaemia not controlled by statin monotherapy

Please sign in to read more